The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future
Open accessAbstract
The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing–thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl 2. PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Siegel, G., Kluba, T., Hermanutz-Klein, U., Bieback, K., Northoff, H., & Schäfer, R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-146 · Cited by 493
Self-citationJ. Centeno, C., R. Schultz, J., Cheever, M., Freeman, M., Faulkner, S., Robinson, B., & Hanson, R. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811797904371 · Cited by 234
Peak Serum: Implications of Serum Supply for Cell Therapy Manufacturing
Brindley, D. A., Davie, N. L., Culme-Seymour, E. J., Mason, C., Smith, D. W., & Rowley, J. A. (2012) · Regenerative Medicine · doi:10.2217/rme.11.112 · Cited by 142
Cited by
Fetal Bovine Serum (FBS): past ‐ present ‐ future
van der Valk, J. (2018) · ALTEX · doi:10.14573/altex.1705101 · Cited by 481
Shen, Z., Kuang, S., Zhang, Y., Yang, M., Qin, W., Shi, X., & Lin, Z. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.07.002 · Cited by 290
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Metadata
- Authors
- Astori, G., Amati, E., Bambi, F., Bernardi, M., Chieregato, K., Schäfer, R., Sella, S., & Rodeghiero, F.
- Venue
- Stem Cell Research & Therapy
- Published
- 2016-07-13
- Volume
- 7
- Issue
- 1
- Pages
- 93-93
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2467927036
- Cited by
- 182
- References
- 5
- FWCI
- 27.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. https://app.cochat.ai/papers/10.1186/s13287-016-0352-x
- The paper
- Astori, G., Amati, E., Bambi, F., Bernardi, M., Chieregato, K., Schäfer, R., Sella, S., & Rodeghiero, F. (2016). Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-016-0352-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.